Manerix (Moclobemide)

Moclobemide selectively and reversibly blocks the enzyme monoamine oxidase A, which normally degrades serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, the drug raises the concentrations of these neurotransmitters in the brain, thereby enhancing mood and alleviating depressive symptoms.

The appropriate dose of Manerix is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient-specific factors.

Manerix is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies any potential risk. Caution is also advised while breastfeeding, and a healthcare professional should evaluate the risk‑benefit ratio.

To order Manerix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with irreversible MAO inhibitors, moclobemide offers a reversible mechanism, resulting in a lower risk of dietary tyramine interactions and a shorter duration of enzyme inhibition. Relative to selective serotonin reuptake inhibitors, it may be chosen when patients have contraindications to those agents or require a different side‑effect profile.

Manerix should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Manerix is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include hypertensive crisis triggered by high‑tyramine foods, serotonin syndrome when combined with other serotonergic drugs, severe liver injury, and rare hematologic disorders such as agranulocytosis. Patients should seek immediate medical attention if they experience sudden severe headache, chest pain, or unexplained fever.

Manerix is contraindicated in patients with known hypersensitivity to moclobemide, those currently using irreversible MAO inhibitors, or individuals with severe liver disease. Caution is also advised for patients with uncontrolled hypertension, pheochromocytoma, or a history of serotonin syndrome.